Using 3D-MRE to assess liver disease and portal hypertension
Three-dimensional MR Elastography for Assessing Cirrhosis and Portal Hypertension (CHESS2206): A Prospective Multicenter Study
This study is testing if a new type of imaging called 3D-MRE can help doctors better understand and manage portal hypertension in patients with cirrhosis and advanced liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT05475015 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of three-dimensional magnetic resonance elastography (3D-MRE) as a non-invasive method to predict hepatic venous pressure gradient (HVPG) in patients with cirrhosis and advanced chronic liver disease. By establishing a risk stratification system, the study aims to improve tailored management for portal hypertension, a critical factor affecting patient outcomes. The research is particularly relevant in China, where liver disease is a significant public health concern, affecting over 400 million individuals. Participants will undergo 3D-MRE imaging within one month prior to HVPG measurement to evaluate the correlation between these two assessments.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with confirmed cirrhosis or advanced chronic liver disease.
Not a fit: Patients with liver cancer, acute portal hypertension, or those who have undergone liver or spleen surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a safer, non-invasive method for monitoring and managing portal hypertension in patients with liver disease.
How similar studies have performed: While the use of 3D-MRE is a novel approach in this context, similar non-invasive imaging techniques have shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria were: (1) ≥18 years; (2) written informed consent; (3) confirmed ACLD of any liver disease etiology; (4) clinically indicated for HVPG measurement, with 3D-MRE performed within one month prior. Exclusion criteria were: (1) hepatic or extrahepatic malignancies, or large hepatic or splenic focal diseases affecting MRE measurement; (2) MR or HVPG contraindications; (3) prior liver or splenic surgery affecting MRE measurement; (4) treatment with nonselective β-blockers (NSBB) between MRE and HVPG measurements; (5) invalid or unreliable HVPG or MRE results and (6) biliary obstruction or dilation on MR images.
Where this trial is running
Shenyang, Liaoning
- Shengjing Hospital — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Principal investigator: Yu Shi, Prof. — Shengjing Hospital
- Study coordinator: Yifei Huang, M.D.
- Email: huangyf1995@foxmail.com
- Phone: +86 158 0000 4518
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.